Neurophyxia's main objective is to develop 2-iminobiotin (or 2-IB) a novel injectable pharmaceutical product to reduce the deleterious effects of oxygen shortage (hypoxia-ischemia) in the brain occurring in three life-threatening conditions:
- Cardiac arrest
- Birth asphyxia
The problem: cerebral reperfusion injury
Hypoxia-ischemia is a biphasic process in which hypoxia-ischemia and the subsequent reperfusion lead to neuronal cell death over hours to days after the initial insult. Currently, there are no neuroprotective agents available to halt this deleterious process and improve brain function.
The solution: 2-iminobiotin
Our neuroprotective agent 2-IB, a selective inhibitor of neuronal and inducible nitric oxide synthase, holds great promise to reduce the reperfusion damage after hypoxic-ischemia in the brain and improve long term outcomes in stroke, cardiac arrest and birth asphyxia.
The neuroprotective effects of 2-IB have been established in preclinical trials in four different animal models. Its excellent safety profile has been demonstrated in clinical trials in adults and newborns. First signs of efficacy have been seen in clinical trials.